Currently, there are two ongoing clinical trials that aim to investigate the efficacy of anti-LAG-3 mAb alone or in combination with anti-PD-L1 mAb in patients with advanced solid tumors including CRC (Table 2). The gene discussed is LAG3; the disease is colorectal carcinoma.